A Chinese-led study has systematically integrated multiple global databases to assess changes in childhood cancer incidence, mortality, and disease burden from 2000 to 2022, while projecting trends through 2050.
The paper, published in CA: A Cancer Journal for Clinicians by a team led by Prof. Jianxing He at the First Affiliated Hospital of Guangzhou Medical University, highlights stark inequality between countries at different stages of development.
Incidence and mortality are generally declining
The study estimated that in 2022 there were 202,164 new cases of childhood cancer worldwide and 77,182 deaths. Leukemia remained the most common and deadliest childhood cancer.
From 2000 to 2021, the age-standardized incidence rate and age-standardized mortality rate of childhood cancer both showed overall declines, with mortality falling more sharply than incidence. Years of life lost and disability-adjusted life years also fell, suggesting improvement in treatment and supportive care.
However, the authors noted that apparent declines during the COVID-19 pandemic may partly reflect delayed diagnosis, interrupted care, and disrupted registration systems rather than true reductions in disease.
A “development reversal”
One of the study's most important findings is that high-income countries have higher reported incidence, but low-income countries have much higher mortality. The authors interpret this as a reflection of better detection and registration in more developed settings and poorer access to diagnosis, treatment, and supportive care in less developed ones.
Measures of inequality showed that the burden remains concentrated in lower-development countries and that the gap has not narrowed appreciably.
Projection to 2050
Using GLOBOCAN data and United Nations population projections, the investigators estimated that by 2050 the world may see about 204,925 new cases and 78,210 deaths from childhood cancer. Leukemia is expected to remain the most common and most deadly category.
Although the overall global increase appears modest, the growth is expected to be concentrated in low-HDI areas. The study estimates that low-HDI regions will account for essentially all growth in case and death counts through 2050.
The authors therefore call for broader coverage of high-quality population-based cancer registries, stronger international cooperation, and more innovative care models, especially in low- and middle-income countries.